Priovant’s brepacitinib is a dual inhibitor of tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1). Image credit: eamesBot / Shutterstock.

Priovant Therapeutics has high expectations for its lead candidate brepocitinib and plans to evaluate the therapy in multiple autoimmune indications.

In 2025, the company is expecting topline data from the Phase III VALOR trial (NCT05437263) evaluating the therapy in dermatomyositis, a rare muscle inflammatory disorder. The company is also running another Phase III CLARITY trial (NCT06431373) evaluating brepocitinib in non-anterior non-infectious uveitis indication.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Priovant’s CEO Benjamin Zimmer, in an interview with the Clinical Trials Arena, highlighted that brepocitinib’s ability to inhibit tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) allows for a “unique” cytokine suppression profile. Thereby, allowing the therapy to suppress several cytokines that are linked to several different autoimmune diseases.

Zimmer said brepocitinib showed efficacy in seven different indications including psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease, in Phase II trials. However, the company prioritised the therapy’s development in dermatomyositis and uveitis citing the “transformative” potential of brepocitinib in these indications.

TYK2/JAK1 inhibitors have been an area of interest for multiple autoimmune indications such as inflammatory bowel disease, psoriasis, psoriatic arthritis, and atopic dermatitis. Whilst most of the autoimmune space is dominated by monoclonal antibodies like AbbVie’s Humira (adalimumab), GlobalData estimates that there are currently 58 TYK2/JAK1 inhibitors in development.

GlobalData is the parent company of Clinical Trials Arena.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The placebo-controlled Phase III VALOR trial has enrolled 241 patients with dermatomyositis. The study’s primary endpoint of total improvement score at 52 weeks, is a resignation endpoint according to Zimmer. The endpoint is a composite that includes six measures of dermatomyositis disease activity.

Secondary endpoints include steroid-sparing effect of brepocitinib, and individual measurements of skin and muscle disease and activity and other organs, even beyond those in the total improvement score.

Zimmer notes that Priovant is also looking to evaluate brepocitinib other conditions but did not disclose any specific indications. Last month, the US Food and Drug Administration (FDA) granted a fast track designation to brepocitinib as a treatment for non-infectious uveitis, based on positive data from the Phase II NEPTUNE trial (NCT05523765). Concurrently, Pirovant also started enrolment in Phase III CLARITY trial, which consists of two sub-studies each enrolling g 150 patients with non-anterior non-infectious uveitis.